petitioner claimed price at Rs.65,000/- per unit, the respondent has averred that after certain point of time it has realised that there is a collusion between the petitioner and some of the staff members of the respondent resulting in receipt of material and part payments made at the price quoted by the petitioner, but thereafter on realisation of the fact that the petitioner has supplied stents at Rs.38,500/- per unit to other peer hospitals, the respondent has raised issue to the petitioner. Along with the reply to the rejoinder, the respondent has filed various vouchers and tax invoices as Annexure 4 (pages 9 to 21) showing that the petitioner has supplied Biomatrix Drug Eluting Stent at a price varying between Rs.37,000 and Rs.38,850/- per unit. Along with the reply to the rejoinder the respondent has also filed e-mail correspondence. Annexure-5 contains one of these correspondences, a perusal of which shows that on 1.12.2012 Sri G.S. Rao of the respondent has addressed a letter to Sri Sanjeev of the petitioner wherein it is stated that in a recent interaction with their peers it was found that the same stent which is being supplied to the respondent, is being supplied by the petitioner to other peer hospitals at a very competitive rate of Rs.25,000/-. In reply to the said letter, on the same day Sri Sanjeev wrote to the effect that the price charged on all his clients are almost similar to the price being charged on the respondent and that as the prices are negotiated in line with the current market dynamics and government policies, there cannot be any revision but still accepting the respondent’s feelings, the petitioner has given a special discount of 5% on all old payments prior to September for one time settlement. He has further assured that he will stand guarantee for any difference in prices if the respondent can substantiate the same with proof. Through e-mail dt.17.8.2012 issued on behalf of the respondent, Dr. G.S. Rao has informed Mr. Sanjeev that as discussed, it is highly unacceptable that the cost of both these stents, which are being supplied to the respondent by the petitioner to the respondent, is very high compared with other FDA approved stents. Through another